Proinflammatory cytokines IL-6 and IL-1β play a pivotal role in the CSS of COVID-19 [17–19], and the relevant cytokines inhibitors were proposed to relieve symptoms in seriously ill patients [20], such as tocilizumab (a humanized monoclonal antibody against the IL-6 receptor) [21], ruxolitinib (a JAK–STAT inhibitor) and Galectin-3 (both IL-6 and TNF-α inhibitor) [22, 23]. The gene discussed is IL6; the disease is COVID-19.